TABLE 2.
Plasma insulin concentrations and metabolic kinetics during basal conditions and during the hyperinsulinemic-euglycemic clamp before and after placebo and leptin treatment
| Placebo |
Leptin |
|||||
|---|---|---|---|---|---|---|
| Low dose (30 mg/day) |
High dose (80 mg/day) |
|||||
| Before | After | Before | After | Before | After | |
| Insulin (mU/L) | ||||||
| Basal | 19.9 ± 3.5 | 17.9 ± 2.9 | 15.1 ± 1.6 | 15.0 ± 0.9 | 17.6 ± 3.3 | 17.3 ± 4.2 |
| Stage 1 | 37.6 ± 3.3 | 41.4 ± 2.0 | 35.9 ± 4.5 | 34.5 ± 2.8 | 33.8 ± 3.1 | 34.5 ± 3.2 |
| Stage 2 | 91.7 ± 3.7 | 92.9 ± 4.0 | 86.1 ± 14.2 | 77.3 ± 5.3 | 81.8 ± 4.4 | 79.7 ± 6.5 |
| Hepatic insulin sensitivity index | 301 ± 41 | 270 ± 37 | 259 ± 21 | 260 ± 18 | 305 ± 61 | 298 ± 82 |
| Endogenous glucose Ra (μmol/kg body wt/min) | ||||||
| Basal | 9.3 ± 0.4 | 9.1 ± 0.3 | 10.8 ± 0.6 | 10.6 ± 0.7 | 10.2 ± 0.5 | 9.9 ± 0.4 |
| Stage 1 | 3.8 ± 0.9 | 2.8 ± 0.8 | 5.1 ± 0.8 | 4.6 ± 0.7 | 5.1 ± 0.6 | 4.4 ± 0.5 |
| Stage 2 | 1.5 ± 0.6 | 1.3 ± 0.4 | 2.8 ± 0.5 | 2.5 ± 0.4 | 2.4 ± 0.9 | 2.2 ± 0.6 |
| Glucose Rd (μmol/kg body wt/min) | ||||||
| Stage 1 | 8.5 ± 1.3 | 9.6 ± 0.7 | 10.1 ± 1.5 | 12.2 ± 0.9 | 7.9 ± 1.2 | 8.6 ± 1.6 |
| Stage 2 | 14.3 ± 3.1 | 17.5 ± 2.5 | 18.4 ± 3.6 | 20.7 ± 3.0 | 16.7 ± 2.4 | 19.1 ± 3.3 |
| Palmitate Ra (μmol/kg body wt/min) | ||||||
| Basal | 1.3 ± 0.1 | 1.2 ± 0.1 | 1.5 ± 0.1 | 1.4 ± 0.2 | 1.3 ± 0.1 | 1.4 ± 0.1 |
| Stage 1 | 0.8 ± 0.1 | 0.6 ± 0.1 | 0.7 ± 0.2 | 0.7 ± 0.2 | 0.8 ± 0.1 | 0.7 ± 0.1 |
| Glycerol Ra (μmol/kg body wt/min) | ||||||
| Basal | 2.8 ± 0.2 | 2.6 ± 0.2 | 3.2 ± 0.3 | 2.9 ± 0.4 | 2.6 ± 0.3 | 2.8 ± 0.3 |
| Stage 1 | 1.9 ± 0.2 | 1.6 ± 0.2 | 2.0 ± 0.3 | 1.9 ± 0.3 | 2.1 ± 0.3 | 1.8 ± 0.3 |
Values are means ± SE. Basal, stage 1, and stage 2 refer to the hyperinsulinemic-euglycemic clamp as described in the text. No group × time (before vs. after) interactions are shown.